RT Journal Article
SR Electronic
T1 Personalized Prescription of ACEI/ARBs for Hypertensive COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.30.20223594
DO 10.1101/2020.10.30.20223594
A1 Dimitris Bertsimas
A1 Alison Borenstein
A1 Luca Mingardi
A1 Omid Nohadani
A1 Agni Orfanoudaki
A1 Bartolomeo Stellato
A1 Holly Wiberg
A1 Pankaj Sarin
A1 Dirk J. Varelmann
A1 Vicente Estrada
A1 Carlos Macaya
A1 Iván J. Núñez Gil
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.10.30.20223594.abstract
AB The COVID-19 pandemic has prompted an international effort to develop and repurpose medications and procedures to effectively combat the disease. Several groups have focused on the potential treatment utility of angiotensin-converting–enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) for hypertensive COVID-19 patients, with inconclusive evidence thus far. We couple electronic medical record (EMR) and registry data of 3,643 patients from Spain, Italy, Germany, Ecuador, and the US with a machine learning framework to personalize the prescription of ACEIs and ARBs to hypertensive COVID-19 patients. Our approach leverages clinical and demographic information to identify hospitalized individuals whose probability of mortality or morbidity can decrease by prescribing this class of drugs. In particular, the algorithm proposes increasing ACEI/ARBs prescriptions for patients with cardiovascular disease and decreasing prescriptions for those with low oxygen saturation at admission. We show that personalized recommendations can improve patient outcomes by 1.0% compared to the standard of care when applied to external populations. We develop an interactive interface for our algorithm, providing physicians with an actionable tool to easily assess treatment alternatives and inform clinical decisions. This work offers the first personalized recommendation system to accurately evaluate the efficacy and risks of prescribing ACEIs and ARBs to hypertensive COVID-19 patients.Highlights− This paper introduces a data-driven approach for personalizing the prescription of ACE inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) for hypertensive COVID-19 patients.− Leveraging an international cohort of more than 3,500 patients, we identify clinical and demographic characteristics that may affect the effectiveness of ACEIs/ARBs for COVID-19 patients, such as low oxygen saturation at admission.− We developed a user-friendly online application that is available to physicians to facilitate interpretation and communication of the results of the algorithm.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHW is supported by the National Science Foundation Graduate Research Fellowship under Grant No. 174530. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors(s) and do not necessarily reflect the views of the National Science Foundation. AB, LM, and AO were partially funded by a grant from the C3.ai Digital Transformation Institute. No further funding was provided for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All independent organizations and the Massachusetts Institute of Technology institutional review boards approved this protocol as minimal-risk research using data collected for standard clinical practice and waived the requirement for informed consent. The survey was anonymous and confidentiality of information was assured. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study are available upon request as they contain potentially identifying or sensitive patient information. This policy follows the restrictions imposed by the the independent healthcare organizations and the Massachusetts Institute of Technology institutional review boards that approved the study. Electronic health record data cannot be shared publicly because they consists of personal information from which it is difficult to guarantee de-identification. As a result, there is a possibility of deductive disclosure of participants and therefore full data access through a public repository is not permitted by the institutions that provided us the data. The data and associated documentation from each collaborating institution can only be made available under a new data sharing agreement with which includes: 1) commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate measures, and 3) a commitment to destroy or return the data after analyses are complete. Requests can be made directly at covidanalytics@mit.edu.